MentalHealthDaily

D-Cycloserine Targets the NMDA Receptors to Enhance Synpatic Plasticity in Hippocampus (2024 Study)

by GLOOM

In the complex and evolving field of neuroscience, the role of synaptic plasticity in psychiatric disorders has garnered significant attention. d-Cycloserine (DCS), a partial agonist of the N-methyl-D-aspartate receptor (NMDAR), emerges as a key player in potentially revolutionizing treatment approaches. Highlights: d-Cycloserine (DCS): Initially an antimicrobial agent, DCS is now known for its role as …

CE-123 vs. R-Modafinil for Cognition: Dopamine Modulators (2023 Study)

by GLOOM

Recent advancements in neuropharmacology have brought to light S-CE-123, a dopamine transporter inhibitor showing remarkable promise in cognitive enhancement. Its emergence alongside R-modafinil, a well-studied compound with a similar target, paves the way for a fascinating comparative study. This duo of compounds, entwined in the complex dance of brain chemistry, offers a glimpse into the …

Caffeine to Prevent Alzheimer’s Disease via Adenosine A2A Receptors? (2023 Review)

by GLOOM

Alzheimer’s Disease (AD), a prevalent form of dementia, poses significant challenges for individuals and healthcare systems worldwide. Current treatments primarily offer symptomatic relief without altering the disease’s progression. However, emerging research suggests that caffeine, a widely consumed psychoactive substance, may have neuroprotective properties against AD. Highlights: Alzheimer’s Disease is the most common form of dementia, …

Comparison of Brexipiprazole vs. Aripiprazole for Treatment-Resistant Depression (2024 Study)

by GLOOM

Antidepressant-resistant major depressive disorder (AR-MDD) poses significant challenges in psychiatric treatment. Antipsychotics like aripiprazole (ARI) and brexpiprazole (BRE) have emerged as effective adjunct therapies that may be more tolerable than older antipsychotics. Highlights: Both Brexipiprazole and Aripiprazole demonstrated better efficacy than placebo in treating AR-MDD in Japanese patients. Brexipiprazole showed a higher discontinuation rate due …

KNT-127 for Anxiety: Delta Opioid Receptor Agonist via PL-BLA Pathway (2023 Study)

by GLOOM

Recent scientific advancements have illuminated the crucial role of the prelimbic cortex to basolateral amygdala (PL-BLA) pathway in regulating anxiety-like behaviors. Utilizing cutting-edge optogenetic techniques and selective delta-opioid receptor (DOP) agonists, researchers have begun to decode the complex neural circuitry underlying anxiety disorders. Highlights: PL-BLA Pathway Significance: The connection between the prelimbic cortex (PL) and …

Morus Alba (White Mulberry): Medical Uses, Health Effects, Mechanisms (2023 Research)

by GLOOM

Morus alba, a member of the Moraceae family, is not only known for its role in sericulture but also for its therapeutic potential. The plant’s traditional uses are backed by scientific research, indicating its effectiveness in various medical conditions. Highlights: Morus alba is utilized in traditional medicine for its analgesic, antibacterial, antidiabetic, and anti-inflammatory properties. …

Low Dose LSD for Depression Treatment: Preliminary Efficacy (2023 Study)

by GLOOM

Recent research exploring the use of low doses of LSD (Lysergic acid diethylamide) in treating depression marks a significant shift in the psychiatric landscape. This innovative approach seeks to understand and harness the potential therapeutic benefits of psychedelics, which were once stigmatized and largely overlooked in clinical settings. Highlights: Study Design: The research employed a …